59 tuberculosis yet tested, including MDR and XDR strains (8). The nanomolar activity and the 60 strong bactericidal effect of BTZ043 make it a promising drug candidate against TB. However,
61
BTZ, like other mycobacterial cell wall inhibitors, appear to be poorly active on non-replicating 62 bacteria and require association with molecules that target this reservoir of latent bacilli (11) .
63
Further experiments are urgently required in preclinical trials with BTZ043 to establish the best 
66
In this study, we investigated the in vitro efficacy of BTZ043 in combination with current 67 TB drugs or drug candidates against log-phase mycobacteria in order to elucidate potential 68 synergistic, antagonistic or additive interactions.
69

MATERIALS AND METHODS
70
Bacterial strains and culture conditions. M. tuberculosis H37Rv, and an isogenic BTZ-71 resistant strain (H37Rv-BTZ-R) that carries a point mutation in dprE1 (C387S), were routinely 
Minimal inhibitory concentrations (MIC).
Determination of compound MIC using the 83 resazurin reduction microplate assay (REMA) was performed as previously described (7).
84
Briefly, bacterial stocks of M. tuberculosis H37Rv were generated from mid-log cultures and antibacterial combination studies (6, 9).
103
Evaluation of compound interactions using colony forming unit (CFU) 104 determination. As described above, bacteria were incubated in the presence of combinations of 105 compounds at their respective MICs (concentrations used in the checkerboard assays) or fractions 106 thereof. As an alternative readout for bacterial viability, bacteria were plated on solid medium 107 (supplemented 7H10) and CFU counts determined after 3 weeks of incubation at 37°C. Compound interactions assessed by CFU counts. To confirm the results found using 125 the checkerboard assay, we also analyzed compound interactions using the number of CFU as a 126 viability readout (Figure 2 ). In agreement with the findings of the checkerboard assay, CFU 127 determination confirmed that BTZ in combination with RIF ( Fig. 2A), INH (Fig. 2B) , PA-824 128 (Fig. 2D) and MXF (Fig. 2E) The mechanism of synergy observed between BTZ043 and TMC207 could be due to on-137 or off-target effects. To assess if the synergy was caused by the activity of BTZ043 on its target,
138
DprE1, the synergistic compound interaction was re-analyzed by performing the CFU assay with 139 an H37Rv mutant (dprE1_C387S) that is fully resistant to BTZ043 (Fig. 3) . The data clearly
140
show that under these conditions there is no longer any synergy between BTZ043 and TMC207, 141 suggesting that inhibition of DprE1 is essential for the interaction. (13), we suggest that the nature of this synergy is also likely to be due to 170 weakening of the cell wall that improves TMC207 penetration. 
